Backs FY24 revenue view $915M-$985M, consensus $961.09M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HALO:
- Halozyme announces Takeda received EC approval for HYQVIA
- Halozyme announces approval for Vydura in Japan
- Halozyme price target lowered to $48 from $61 at H.C. Wainwright
- Halozyme: Takeda receives FDA approval of HYQVIA co-formulated with ENHANZE
- Halozyme announces Roche receives EC marketing authorization of Tecentriq SC
